Chat with this insight
Save time and jump to the most important pieces.
Recent Analyst Ratings for $OGI
Date | Price Target | Rating | Analyst |
---|---|---|---|
7/17/2024 | Speculative Buy | Canaccord Genuity | |
4/15/2024 | Neutral → Buy | Alliance Global Partners | |
1/13/2023 | Hold → Buy | Stifel | |
1/12/2022 | Hold → Speculative Buy | Canaccord Genuity | |
1/12/2022 | $5.70 → $5.30 | Overweight | Cantor Fitzgerald |
12/8/2021 | $5.50 → $5.70 | Overweight | Cantor Fitzgerald |
Organigram Reports First Quarter Fiscal 2025 Results
17% growth in net revenue to $42.7 million year-over-year $2.3 million growth in international sales year-over-year Adjusted EBITDA1 of $1.4 million versus $0.1 million in the prior year period Completed acquisition of Motif to become recreational cannabis market leader in Canada Launched Edison Sonics with proprietary FAST™ nanoemulsion technology, clinically validated to have up to 50% faster onset and nearly 2x impact of cannabinoids at peak Strong balance sheet with negligible debt, and a pro-forma cash position of $113 million2 Organigram Holdings Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), a leading licensed producer of cannabis, announced its resu
Organigram to Report First Quarter Fiscal 2025 Results on February 11, 2025
Organigram Holdings Inc. (NASDAQ:OGI) (TSX:OGI), the parent company of Organigram Inc. (together, the "Company" or "Organigram"), a leading licensed producer of cannabis, announced today it will report earnings results for its first quarter fiscal 2025 ended December 31, 2024, on Tuesday, February 11, 2025, prior to market open. The Company will host a conference call to discuss its results with details as follows: Date: Tuesday, February 11, 2025 Time: 8:00 am Eastern Time To register for the conference call, please use this link: https://registrations.events/direct/Q4I967665 To ensure you are connected for the full call, we suggest registering a day in advance or at minimum 10 min
Organigram Reports Fourth Quarter and Fiscal 2024 Results
Fiscal 2024 net revenue of $159.8 million 17.6% year-over-year growth in Organigram's recreational shipped sales in Fiscal 2024 Q4 Fiscal 2024 adjusted gross margin1 of 37% Q4 Fiscal 2024 adjusted EBITDA2 of $5.9 million or 13% of net revenue Q4 Fiscal 2024 cash flow from operations of $8.9 million Became Canada's largest cannabis company by market share following the acquisition of Motif Labs subsequent to year end Organigram Holdings Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), a leading licensed producer ("LP") of cannabis, announced its results for the fourth quarter and twelve months ended September 30, 2024 ("Q4 Fiscal 2024" or "Fiscal 2024"). All f
Canaccord Genuity resumed coverage on OrganiGram
Canaccord Genuity resumed coverage of OrganiGram with a rating of Speculative Buy
OrganiGram upgraded by Alliance Global Partners
Alliance Global Partners upgraded OrganiGram from Neutral to Buy
OrganiGram upgraded by Stifel
Stifel upgraded OrganiGram from Hold to Buy
SEC Form 6-K filed by Organigram Holdings Inc.
6-K - ORGANIGRAM HOLDINGS INC. (0001620737) (Filer)
SEC Form 6-K filed by Organigram Holdings Inc.
6-K - ORGANIGRAM HOLDINGS INC. (0001620737) (Filer)
Amendment: SEC Form 40-F/A filed by Organigram Holdings Inc.
40-F/A - ORGANIGRAM HOLDINGS INC. (0001620737) (Filer)
Organigram Announces Appointment of Craig Harris to Board of Directors
Organigram Holdings Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), a leading licensed producer of cannabis, announced the appointment of Craig Harris to the Organigram Board of Directors effective today. Craig brings over 20 years of experience as a commercial lawyer, with a background in private practice and legal and regulatory engagement roles for various corporations. He is currently the Assistant General Counsel – Corporate & Commercial Legal at British American Tobacco plc (BAT). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240729497569/en/Craig Harris (Photo: Business Wire) "We are thrilled to welcome Cra
Organigram Announces Appointment of Karina Gehring to Board of Directors
Organigram Holdings Inc. ("Organigram" or the "Company") (TSX:OGI) (NASDAQ:OGI), announced the appointment of Karina Gehring to the Organigram Board of Directors at the Company's annual general and special meeting held on January 18, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240119151071/en/Karina Gehring (Photo: Business Wire) "We are thrilled to welcome Karina to our Board of Directors. Her extensive expertise in marketing and brand management combined with her ongoing experience with BAT will be a tremendous asset to our Board," said Peter Amirault, Board Chair, Organigram. Karina is one of two directors (includi
Organigram Announces Results of Annual and Special Meeting, including Shareholder Approval of C$124.6 Million Investment from BAT
Organigram Holdings Inc. ("Organigram" or the "Company") (TSX:OGI) (NASDAQ:OGI) announced today the results of voting at its annual general and special meeting of shareholders (the "Shareholders") held virtually on January 18, 2024 (the "Meeting"). Election of Directors Each of the nine nominees listed in the Company's management information circular dated December 20, 2023 (the "Circular") provided in connection with the Meeting were elected as directors of the Company. The Company received proxies and virtual votes at the Meeting as set out below: Nominee # Votes For % of Votes For # Votes Against % of Votes Against Peter Amirault 21,048,219
Organigram Reports First Quarter Fiscal 2025 Results
17% growth in net revenue to $42.7 million year-over-year $2.3 million growth in international sales year-over-year Adjusted EBITDA1 of $1.4 million versus $0.1 million in the prior year period Completed acquisition of Motif to become recreational cannabis market leader in Canada Launched Edison Sonics with proprietary FAST™ nanoemulsion technology, clinically validated to have up to 50% faster onset and nearly 2x impact of cannabinoids at peak Strong balance sheet with negligible debt, and a pro-forma cash position of $113 million2 Organigram Holdings Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), a leading licensed producer of cannabis, announced its resu
Organigram to Report First Quarter Fiscal 2025 Results on February 11, 2025
Organigram Holdings Inc. (NASDAQ:OGI) (TSX:OGI), the parent company of Organigram Inc. (together, the "Company" or "Organigram"), a leading licensed producer of cannabis, announced today it will report earnings results for its first quarter fiscal 2025 ended December 31, 2024, on Tuesday, February 11, 2025, prior to market open. The Company will host a conference call to discuss its results with details as follows: Date: Tuesday, February 11, 2025 Time: 8:00 am Eastern Time To register for the conference call, please use this link: https://registrations.events/direct/Q4I967665 To ensure you are connected for the full call, we suggest registering a day in advance or at minimum 10 min
Organigram Reports Fourth Quarter and Fiscal 2024 Results
Fiscal 2024 net revenue of $159.8 million 17.6% year-over-year growth in Organigram's recreational shipped sales in Fiscal 2024 Q4 Fiscal 2024 adjusted gross margin1 of 37% Q4 Fiscal 2024 adjusted EBITDA2 of $5.9 million or 13% of net revenue Q4 Fiscal 2024 cash flow from operations of $8.9 million Became Canada's largest cannabis company by market share following the acquisition of Motif Labs subsequent to year end Organigram Holdings Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), a leading licensed producer ("LP") of cannabis, announced its results for the fourth quarter and twelve months ended September 30, 2024 ("Q4 Fiscal 2024" or "Fiscal 2024"). All f
Amendment: SEC Form SC 13D/A filed by Organigram Holdings Inc.
SC 13D/A - ORGANIGRAM HOLDINGS INC. (0001620737) (Subject)
Amendment: SEC Form SC 13D/A filed by Organigram Holdings Inc.
SC 13D/A - ORGANIGRAM HOLDINGS INC. (0001620737) (Subject)
SEC Form SC 13D/A filed by Organigram Holdings Inc. (Amendment)
SC 13D/A - ORGANIGRAM HOLDINGS INC. (0001620737) (Subject)